Sherwin K. B. Sy

List of Publications by Year
in descending order

61	970	430874	552781
papers	citations	18 h-index	26 g-index

61	61	61	1277
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Use of a sparse sampling study design to assess transfer of tramadol and its O-desmethyl metabolite into transitional breast milk. British Journal of Clinical Pharmacology, 2008, 65, 661-666.	2.4	53
2	Mycobacterium tuberculosis Strains H37ra and H37rv have equivalent minimum inhibitory concentrations to most antituberculosis drugs. International Journal of Mycobacteriology, 2018, 7, 156.	0.6	48
3	Pharmacokinetics and pharmacodynamics in antibiotic dose optimization. Expert Opinion on Drug Metabolism and Toxicology, 2016, 12, 93-114.	3.3	46
4	Modeling of human hepatic CYP3A4 enzyme kinetics, protein, and mRNA indicates deviation from log-normal distribution in CYP3A4 gene expression. European Journal of Clinical Pharmacology, 2002, 58, 357-365.	1.9	38
5	Pharmacodynamic Evaluation of the Potential Clinical Utility of Fosfomycin and Meropenem in Combination Therapy against KPC-2-Producing Klebsiella pneumoniae. Antimicrobial Agents and Chemotherapy, 2016, 60, 4128-4139.	3.2	37
6	In vitropharmacokinetics/pharmacodynamics of the combination of avibactam and aztreonam against MDR organisms. Journal of Antimicrobial Chemotherapy, 2016, 71, 1866-1880.	3.0	35
7	Population pharmacokinetic modeling of tramadol and its O-desmethyl metabolite in plasma and breast milk. European Journal of Clinical Pharmacology, 2011, 67, 899-908.	1.9	32
8	Pharmacokinetics ofpara-Aminosalicylic Acid in HIV-Uninfected and HIV-Coinfected Tuberculosis Patients Receiving Antiretroviral Therapy, Managed for Multidrug-Resistant and Extensively Drug-Resistant Tuberculosis. Antimicrobial Agents and Chemotherapy, 2014, 58, 6242-6250.	3.2	31
9	Clinical Pharmacokinetics and Pharmacodynamics of Ceftazidimeâ€“Avibactam Combination: A Model-Informed Strategy for its Clinical Development. Clinical Pharmacokinetics, 2019, 58, 545-564.	3.5	30
10	Pharmacodynamic Attainment of the Synergism of Meropenem and Fosfomycin Combination against Pseudomonas aeruginosa Producing Metallo-Î²-Lactamase. Antimicrobial Agents and Chemotherapy, 2019, 63, .	3.2	30
11	N -Acetyltransferase Genotypes and the Pharmacokinetics and Tolerability of para -Aminosalicylic Acid in Patients with Drug-Resistant Pulmonary Tuberculosis. Antimicrobial Agents and Chemotherapy, 2015, 59, 4129-4138.	3.2	27
12	Pharmacodynamic Evaluation of Fosfomycin against Escherichia coli and Klebsiella spp. from Urinary Tract Infections and the Influence of pH on Fosfomycin Activities. Antimicrobial Agents and Chemotherapy, 2017, 61, .	3.2	26
13	Prediction ofin vivoandin vitroinfection model results using a semimechanistic model of avibactam and aztreonam combination against multidrug resistant organisms. CPT: Pharmacometrics and Systems Pharmacology, 2017, 6, 197-207.	2.5	24
14	A mathematical model-based analysis of the timeâ€“kill kinetics of ceftazidime/avibactam against Pseudomonas aeruginosa. Journal of Antimicrobial Chemotherapy, 2018, 73, 1295-1304.	3.0	24
15	Pharmacodynamic Effects of Sulbactam/Meropenem/Polymyxin-B Combination Against Extremely Drug Resistant Acinetobacter baumannii Using Checkerboard Information. Microbial Drug Resistance, 2019, 25, 1266-1274.	2.0	23
16	Evaluation of in vitro synergy between vertilmicin and ceftazidime against Pseudomonas aeruginosa using a semi-mechanistic pharmacokinetic/pharmacodynamic model. International Journal of Antimicrobial Agents, 2015, 45, 151-160.	2.5	21
17	Gentamicin dosing strategy in patients with end-stage renal disease receiving haemodialysis: evaluation using a semi-mechanistic pharmacokinetic/pharmacodynamic model. Journal of Antimicrobial Chemotherapy, 2016, 71, 1012-1021.	3.0	21
18	Population Pharmacokinetic and Covariate Analysis of Apatinib, an Oral Tyrosine Kinase Inhibitor, in Healthy Volunteers and Patients with Solid Tumors. Clinical Pharmacokinetics, 2017, 56, 65-76.	3.5	21

#	Article	IF	Citations
19	Dose optimization of moxifloxacin and linezolid against tuberculosis using mathematical modeling and simulation. International Journal of Antimicrobial Agents, 2019, 53, 275-283.	2.5	21
20	The Use of Roxifiban (DMP754), a Novel Oral Platelet Glycoprotein IIb/IIIa Receptor Inhibitor, in Patients with Stable Coronary Artery Disease. American Journal of Cardiovascular Drugs, 2003, 3, 101-112.	2.2	18
21	Potentiation of ceftazidime by avibactam against Î²-lactam-resistantPseudomonas aeruginosain anin vitroinfection model. Journal of Antimicrobial Chemotherapy, 2017, 72, dkw535.	3.0	18
22	Change in Topoisomerase 1â€“Positive Circulating Tumor Cells Affects Overall Survival in Patients with Advanced Breast Cancer after Treatment with Etirinotecan Pegol. Clinical Cancer Research, 2018, 24, 3348-3357.	7.0	18
23	Experimental design and modelling approach to evaluate efficacy of Î²-lactam/Î²-lactamase inhibitor combinations. Clinical Microbiology and Infection, 2018, 24, 707-715.	6.0	16
24	Simultaneous quantification of seven active metabolites of roxifiban in human plasma by LC/MS/MS in the presence of an interfering displacer at millimolar concentrations. Journal of Pharmaceutical and Biomedical Analysis, 2003, 31, 937-951.	2.8	15
25	Largazole Pharmacokinetics in Rats by LC-MS/MS. Marine Drugs, 2014, 12, 1623-1640.	4.6	15
26	Predicting Pediatric Age-Matched Weight and Body Mass Index. AAPS Journal, 2014, 16, 1372-1379.	4.4	15
27	Physiologicallyâ€based pharmacokinetics of ziprasidone in pregnant women. British Journal of Clinical Pharmacology, 2019, 85, 914-923.	2.4	15
28	Physiologically based pharmacokineticâ€pharmacodynamic evaluation of meropenem plus fosfomycin in paediatrics. British Journal of Clinical Pharmacology, 2021, 87, 1012-1023.	2.4	15
29	Characterization of intestinal absorption of C -glycoside flavonoid vicenin-2 from Lychnophora ericoides leafs in rats by nonlinear mixed effects modeling. Revista Brasileira De Farmacognosia, 2015, 25, 212-218.	1.4	14
30	Fixed-dose combinations: a potential means to boost drug development for selected drugs. Drug Discovery Today, 2018, 23, 457-459.	6.4	14
31	Aztreonam/avibactam effect on pharmacodynamic indices for mutant selection ofEscherichia coli and Klebsiella pneumoniaeharbouring serine- and New Delhi metallo-Î²-lactamases. Journal of Antimicrobial Chemotherapy, 2021, 76, 2875-2883.	3.0	14
32	A Markov Chain Model to Evaluate the Effect of CYP3A5 and ABCB1 Polymorphisms on Adverse Events Associated with Tacrolimus in Pediatric Renal Transplantation. AAPS Journal, 2013, 15, 1189-1199.	4.4	13
33	Pharmacometrics in Bacterial Infections. AAPS Advances in the Pharmaceutical Sciences Series, 2014, , 229-258.	0.6	13
34	Safety, Tolerability, Pharmacokinetics, and Time Course of Pharmacologic Response of the Active Metabolite of Roxifiban, XV459, a Glycoprotein IIb/IIIa Antagonist, following Oral Administration in Healthy Volunteers. Journal of Clinical Pharmacology, 2002, 42, 738-753.	2.0	12
35	Effect of reducing the paediatric stavudine dose by half: A physiologically-based pharmacokinetic model. International Journal of Antimicrobial Agents, 2015, 45, 413-419.	2.5	11
36	Detailed characterization of experimentally derived human hepatic CYP1A1 activity and expression using differential inhibition of ethoxyresorufin O-deethylation by fluvoxamine. European Journal of Clinical Pharmacology, 2001, 57, 377-386.	1.9	10

#	Article	IF	Citations
37	Principles of Applied Pharmacokineticâ€“Pharmacodynamic Modeling. , 2014, , 63-79.		10
38	Learning and augmenting natural processes: potential means of combating antimicrobial resistance from a drug R&D perspective. Drug Discovery Today, 2020, 25, 1-3.	6.4	10
39	Estimation of Intracellular Concentration of Stavudine Triphosphate in HIV-Infected Children Given a Reduced Dose of 0.5 Milligrams per Kilogram Twice Daily. Antimicrobial Agents and Chemotherapy, 2014, 58, 1084-1091.	3.2	9
40	Application of Pharmacometric Analysis in the Design of Clinical Pharmacology Studies for Biosimilar Development. AAPS Journal, 2018, 20, 40.	4.4	9
41	Introduction to Pharmacometrics and Quantitative Pharmacology with an Emphasis on Physiologically Based Pharmacokinetics. AAPS Advances in the Pharmaceutical Sciences Series, 2014, , 1-64.	0.6	8
42	Quantitation of the impact of CYP3A5 A6986G polymorphism on quetiapine pharmacokinetics by simulation of target attainment. Clinical Pharmacology in Drug Development, 2015, 4, 387-394.	1.6	8
43	Pharmacokinetic Evaluation of Avicularin Using a Model-Based Development Approach. Planta Medica, 2015, 81, 373-381.	1.3	8
44	Simultaneous Characterization of Intravenous and Oral Pharmacokinetics of Lychnopholide in Rats by Transit Compartment Model. Planta Medica, 2015, 81, 1121-1127.	1.3	8
45	Exposureâ€“Efficacy Analysis of Asciminib in Philadelphia Chromosomeâ€“Positive Chronic Myeloid Leukemia in Chronic Phase. Clinical Pharmacology and Therapeutics, 2022, 112, 1040-1050.	4.7	8
46	Pharmacokinetics I: PK-PD Approach, the Case of Antibiotic Drug Development. , 2016, , 185-217.		7
47	In silico labeling reveals the time-dependent label half-life and transit-time in dynamical systems. BMC Systems Biology, 2012, 6, 13.	3.0	6
48	Etirinotecan pegol administration is associated with lower incidences of neutropenia compared to irinotecan administration. Cancer Chemotherapy and Pharmacology, 2017, 79, 57-67.	2.3	6
49	Population Pharmacokinetics of Asciminib in Tyrosine Kinase Inhibitor-Treated Patients with Philadelphia Chromosome-Positive Chronic Myeloid Leukemia in Chronic and Acute Phases. Clinical Pharmacokinetics, 2022, 61, 1393-1403.	3.5	6
50	Influence of CYP3A5 6986Aâ€‰>â€‰G and ABCB1 3435Câ€‰>â€‰T Polymorphisms on Adverse Events Associated With Tacrolimus in Jordanian Pediatric Renal Transplant Patients. Clinical Pharmacology in Drug Development, 2013, 2, 67-78.	1.6	5
51	Pharmacokinetics, Pharmacodynamics and Dermal Distribution of 5-Methoxypsoralen Based on a Physiologically Based Pharmacokinetic Model to Support Phytotherapy Using Brosimum gaudichaudii. Planta Medica, 2020, 86, 276-283.	1.3	5
52	Electroencephalogram effects of armodafinil: Comparison with behavioral alertness. Journal of Clinical Pharmacology, 2013, 53, 1058-1071.	2.0	4
53	Modelâ€informed drug development for immunoâ€oncology agonistic <scp>antiâ€GITR</scp> antibody <scp>GWN323</scp>: Dose selection based on <scp>MABEL</scp> and biologically active dose. Clinical and Translational Science, 2022, 15, 2218-2229.	3.1	4
54	Multivariate cluster analysis of a human hepatic cytochrome P 450 database. European Journal of Clinical Pharmacology, 2002, 58, 559-562.	1.9	3

#	Article	IF	Citations
55	A Perspective on the Toxicological Mechanisms Possibly Contributing to the Failure of Oral Glycoprotein IIb/IIIa Antagonists in the Clinic. American Journal of Cardiovascular Drugs, 2004, 4, 1-10.	2.2	3
56	Florfenicol/Chlortetracycline Effect on Pharmacodynamic Indices for Mutant Selection of Riemerella anatipestifer in Ducks. Microbial Drug Resistance, 2022, 28, 832-840.	2.0	3
57	Rapid and efficient method for the quantification of lychnopholide in rat plasma by liquid chromatographyâ€“tandem mass spectrometry for pharmacokinetic application. Biomedical Chromatography, 2016, 30, 1092-1096.	1.7	2
58	Integrated population pharmacokinetics of etirinotecan pegol and its four metabolites in cancer patients with solid tumors. Cancer Chemotherapy and Pharmacology, 2018, 81, 897-909.	2.3	2
59	Melanogenic Effect and Toxicity Assessments of Standardized Extract of Brosimum gaudichaudii. Revista Brasileira De Farmacognosia, 2020, 30, 597-601.	1.4	1
60	Application of Trial Simulation in the Design of a Prospective Study for Concentration-QTc Analysis in Support of a Thorough QT Study Waiver. AAPS Journal, 2020, 22, 101.	4.4	1
61	Pharmacokinetic-Pharmacodynamic Characterization of a Topical Photochemotherapy Using Brosimum gaudichaudii in C56BL/6 Mice. Revista Brasileira De Farmacognosia, 2021, 31, 184-192.	1.4	0